Extended-Duration Low-Intensity Apixaban to Prevent Recurrence in High-Risk Patients With Provoked Venous Thromboembolism
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 600 participants.
Also called NCT04168203
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 600 participants
- Sponsor
- Registry
-
NCT04168203
-
- Other papers using this trial's data
- Apixaban for Extended Treatment of Provoked Venous Thromboembolism
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States
- Registry status
- Completed
Technical summary
Registry record NCT04168203. Randomized; quadruple masking; primary purpose treatment. Start 2021-03-01 (actual); primary completion 2023-11-30 (actual). Results posted on 2025-09-30.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Extended-Duration Low-Intensity Apixaban to Prevent Recurrence in High-Risk Patients With Provoked Venous Thromboembolism
- Acronym
- HI-PRO
- Condition
- Deep Vein Thrombosis
- Condition
- Pulmonary Embolism
- Condition
- Venous Thromboembolism
- Intervention (Drug)
- Apixaban 2.5 MG
- Intervention (Drug)
- Placebo oral tablet
- Lead sponsor
- Brigham and Women's Hospital
Record details
- Record id
cardio:ct-nct04168203- Content hash
c64f454cf97c9f6c7b967b249cfe7c47f44cbc20a0776b27bf639719d904496a